Selective Mastectomy in the Management of Locally Advanced Breast Cancer

Verity Ahern*, John Boyages, Val Gebski, Dominic Moon, Nicholas Wilcken

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To evaluate local control for patients with locally advanced noninflammatory breast cancer (LABC) managed by selective mastectomy. Methods and Materials: Between 1979 and 1996, 176 patients with LABC were prospectively managed by chemotherapy (CT)-irradiation (RT)-CT without routine mastectomy. All surviving patients were followed for a minimum of 5 years. Results: A total of 132 patients (75%) had a T4 tumor and 22 (12.5%) supraclavicular nodal disease. The clinical complete response rate was 91% (160/176), which included 13 patients who underwent mastectomy and 2 an iridium wire implant. The first site of failure was local for 43 patients (breast ± axilla for 38); 27 of these patients underwent salvage mastectomy and 11 did not for an overall mastectomy rate of 23% (40/176). If all 176 patients had undergone routine mastectomy (136 extra mastectomies), 11 additional patients may have avoided an unsalvageable first local relapse. The others would have either have not had a local relapse or would have suffered local relapse after distant disease. No tumor or treatment related factor was found to predict local disease at death. Median disease-free and overall survival for all patients was 26 and 52 months, respectively. Conclusions: Selective mastectomy in LABC may not jeopardize local control or survival.

Original languageEnglish
Pages (from-to)1010-1017
Number of pages8
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume68
Issue number4
DOIs
Publication statusPublished - 15 Jul 2007
Externally publishedYes

Keywords

  • Chemotherapy
  • Locally advanced noninflammatory breast cancer
  • Mastectomy
  • Radiotherapy

Fingerprint Dive into the research topics of 'Selective Mastectomy in the Management of Locally Advanced Breast Cancer'. Together they form a unique fingerprint.

Cite this